The DOI matches its OpenAlex record; 39 of the 39 references it cites were found in a registry or an index.
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
Open accessAbstract
Nonmelanoma skin cancer is one of the most common malignancies in humans. Different therapeutic strategies for the treatment of these tumors are currently being investigated. Given the growth-inhibiting effects of cannabinoids on gliomas and the wide tissue distribution of the two subtypes of cannabinoid receptors (CB(1) and CB(2)), we studied the potential utility of these compounds in anti-skin tumor therapy. Here we show that the CB(1) and the CB(2) receptor are expressed in normal skin and skin tumors of mice and humans. In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB(1)/CB(2) agonist WIN-55,212-2 or the selective CB(2) agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells. This was accompanied by impairment of tumor vascularization, as determined by altered blood vessel morphology and decreased expression of proangiogenic factors (VEGF, placental growth factor, and angiopoietin 2). Abrogation of EGF-R function was also observed in cannabinoid-treated tumors. These results support a new therapeutic approach for the treatment of skin tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 2×
“For that purpose they produce proangiogenic factors that promote the formation of new blood vessels (28, 29).”
BackgroundIsolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“As shown in Figure 1b, the peptides blocked anti-CB1 and anti-CB2 Ab binding, not only in skin-derived samples but also in other cell types used as well-established controls for the presence of CB1 (rat cortical neurons) (18), CB2 (human promyelocytic HL60 cells) (19), and CB1 plus CB2 (rat C6 glioma cells) (21).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 2×
“For that purpose they produce proangiogenic factors that promote the formation of new blood vessels (28, 29).”
BackgroundMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Galve-Roperh, I., Sánchez, C., Cortés, M. L., del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000) · Nature Medicine · doi:10.1038/73171 · Cited by 682
Self-citationTGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
Luetteke, N. C., Qiu, T. H., Peiffer, R. L., Oliver, P., Smithies, O., & Lee, D. C. (1993) · Cell · doi:10.1016/0092-8674(93)90228-i · Cited by 659
Epidermal differentiation: the bare essentials.
Fuchs, E. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.6.2807 · Cited by 658
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanuš, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 571
The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase.
Luetteke, N. C., Phillips, H. K., Qiu, T. H., Copeland, N. G., Earp, H. S., Jenkins, N. A., & Lee, D. C. (1994) · Genes & Development · doi:10.1101/gad.8.4.399 · Cited by 441
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez, C., CEBALLOS, M. L. D., del Pulgar, T. G., Rueda, D., Corbacho, C., Velasco, G., Galve‐Roperh, I., Huffman, J. W., y Cajal, S. R., & Guzmán, M. (2001) · Cancer Research · Cited by 422
Self-citationThe endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
CB2 cannabinoid receptor-mediated peripheral antinociception
Malan, P. T., Ibrahim, M. M., Deng, H., Liu, Q., Mata, H. P., Vanderah, T., Porreca, F., & Makriyannis, A. (2001) · Pain · doi:10.1016/s0304-3959(01)00321-9 · Cited by 391
Antineoplastic Activity of Cannabinoids2
Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L., & Carchman, R. A. (1975) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/55.3.597 · Cited by 348
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., & Marmé, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25915 · Cited by 329
The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development
Sibilia, M., Fleischmann, A., Behrens, A., Stingl, L., Carroll, J., Watt, F. M., Schlessinger, J., & Wagner, E. F. (2000) · Cell · doi:10.1016/s0092-8674(00)00026-x · Cited by 304
The EGF receptor - an essential regulator of multiple epidermal functions.
Jost, M., Kari, C., & Rodeck, U. (2000) · PubMed · Cited by 302
Huffman, J. W., Liddle, J., Yu, S., Aung, M. M., Abood, M. E., Wiley, J. L., & Martin, B. R. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00219-9 · Cited by 288
Self-citationZhang, H.-T., Craft, P., Scott, P. A. E., Ziche, M., Weich, H. A., Harris, A. L., & Bicknell, R. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.3.213 · Cited by 265
Murillas, R., Larcher, F., Conti, C. J., Santos, M., Ullrich, A., & Jorcano, J. L. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00206.x · Cited by 249
Self-citationLarcher, F., Murillas, R., Bolontrade, M., Conti, C. J., & Jorcano, J. L. (1998) · Oncogene · doi:10.1038/sj.onc.1201928 · Cited by 231
Self-citationThe endocannabinoid nervous system
Porter, A. C., & Felder, C. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00130-9 · Cited by 227
Control of the cell survival/death decision by cannabinoids
Guzmán, M., Sánchez, C., & Galve-Roperh, I. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090000177 · Cited by 223
Self-citationPhotodynamic Therapy of Skin Cancers: Sensitizers, Clinical Studies and Future Directives
De Rosa, F. S., & Bentley, M. V. L. B. (2000) · Pharmaceutical Research · doi:10.1023/a:1007612905378 · Cited by 211
Pertwee, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.7.1553 · Cited by 208
Blázquez, C., Galve‐Roperh, I., & Guzmán, M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0122com · Cited by 160
Self-citationHawighorst, T., Velasco, P., Streit, M., Hong, Y., Kyriakides, T. R., Brown, L. F., Bornstein, P., & Detmar, M. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2631 · Cited by 148
Control by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth
Bifulco, M., Laezza, C., Portella, G., Vitale, M., Orlando, P., PETROCELLIS, L. D., & Marzo, V. D. (2001) · The FASEB Journal · doi:10.1096/fj.01-0320fje · Cited by 140
Hunts, J., Ueda, M., Ozawa, S., Abe, O., Pastan, I. H., & Shimizu, N. (1985) · PubMed · Cited by 139
Larcher, F., Robles, A. I., Durán, H., Murillas, R., Quintanilla, M., Cano, A., Conti, C. J., & Jorcano, J. L. (1996) · PubMed · Cited by 120
Self-citationCasanova, M., Larcher, F., Casanova, B., Murillas, R., Fernández‐Aceñero, M. J., Villanueva, C., Martínez‐Palacio, J., Ullrich, A., Conti, C. J., & Jorcano, J. L. (2002) · PubMed · Cited by 110
Self-citationMorris, R. J., Tryson, K. A., & Wu, K. Q. (2000) · PubMed · Cited by 108
Angiogenesis is an early event in the development of chemically induced skin tumors
Bolontrade, M. F. (1998) · Carcinogenesis · doi:10.1093/carcin/19.12.2107 · Cited by 69
Common skin cancers in the United States: a practical guide for diagnosis and treatment.
Leber, K., Vd, P., & McKeehen, B. (1999) · PubMed · Cited by 7
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…tumor or tumor cell xenografts in vivo, including lung carcinoma (Munson et al., 1975), glioma (Galve-Roperh et al., 2000; Sánchez et al., 2001a; Massi et al., 2004), thyroid epithelioma (Bifulco et al., 2001), lymphoma (McKallip et al., 2002a), and skin carcinoma (Casanova et al., 2003) in mice.”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
An empirical Bayes approach to inferring large-scale gene association networks
Schäfer, J., & Strimmer, K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti062 · Cited by 795
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Self-citationβ‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
Fidyt, K., Fiedorowicz, A., Strządała, L., & Szumny, A. (2016) · Cancer Medicine · doi:10.1002/cam4.816 · Cited by 674
Metadata
- Authors
- Casanova, M., Blázquez, C., Martínez‐Palacio, J., Villanueva, C., Fernández‐Aceñero, M. J., Huffman, J. W., Jorcano, J. L., & Guzmán, M.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2003-01-01
- Volume
- 111
- Issue
- 1
- Pages
- 43-50
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2113996941
- Cited by
- 437
- References
- 39
- FWCI
- 15.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.